NCT06449625View on ClinicalTrials.gov

Semaglutide in Auto-HSCT

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 12, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

February 1, 2027

Conditions
Intestinal MucositisInflammationChemotherapeutic Toxicity
Interventions
DRUG

Semaglutide Pen Injector [Ozempic]

Semaglutide active drug

DRUG

Placebo

semaglutide placebo

Sponsors

Collaborators (1)

Novo Nordisk A/S
All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

collaborator

Independent Research Fund Denmark

INDUSTRY

lead

Klaus Gottlob Müller

OTHER